213 related articles for article (PubMed ID: 15664500)
1. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
2. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
7. In vivo studies on the utilization of mono-L-aspartyl chlorin (NPe6) for photodynamic therapy.
Nelson JS; Roberts WG; Berns MW
Cancer Res; 1987 Sep; 47(17):4681-5. PubMed ID: 2957047
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
9. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
10. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
11. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398.
Harvey EH; Webber J; Kessel D; Fromm D
Am J Surg; 2005 Mar; 189(3):302-5. PubMed ID: 15792755
[TBL] [Abstract][Full Text] [Related]
12. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
14. [A basic study of photodynamic therapy of experimental hepatoma with ME 2906].
Nakamura J; Kajiwara H; Nakamura M; Watanabe M; Naganuma K; Tanaka H; Usui S; Sumiyama Y; Saito K; Aizawa K
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1454-6. PubMed ID: 9703852
[TBL] [Abstract][Full Text] [Related]
15. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
Mori K; Ohta M; Sano A; Yoneya S; Sonoda M; Kaneda A; Sato Y
Nippon Ganka Gakkai Zasshi; 1997 Feb; 101(2):134-40. PubMed ID: 9124093
[TBL] [Abstract][Full Text] [Related]
16. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
17. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
Ohtani K; Usuda J; Ichinose S; Ishizumi T; Hirata T; Inoue T; Maehara S; Imai K; Kubota M; Tsunoda Y; Yamada M; Tsutsui H; Yamada K; Kuroiwa Y; Furukawa K; Okunaka T; Kato H
Int J Oncol; 2008 Feb; 32(2):397-403. PubMed ID: 18202762
[TBL] [Abstract][Full Text] [Related]
18. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M
J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422
[TBL] [Abstract][Full Text] [Related]
19. Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines.
Nakamura H; Suzuki Y; Takeichi M; Saito T; Takayama M; Aizawa K
Int J Gynecol Cancer; 2002; 12(2):177-86. PubMed ID: 11975677
[TBL] [Abstract][Full Text] [Related]
20. Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer.
Chin WW; Heng PW; Thong PS; Bhuvaneswari R; Hirt W; Kuenzel S; Soo KC; Olivo M
Eur J Pharm Biopharm; 2008 Aug; 69(3):1083-93. PubMed ID: 18396019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]